Efficacy and Safety of Dorocontin(®) versus Sustac(®) in the Treatment of Stable Angina Pectoris: A Randomized, Double-Blind Comparative Trial.

Sci Pharm · 2014 · PMC4475798 · PMID 26171326

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Frequencies of ECG abnormalities including ST depression and inverted T were reduced in the Dorocontin ® group in a borderline significant manner, but there was no change in the Sustac ® group.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.